Table S1.
Baseline clinical data of 52 patients with advanced HCC
| Presentation | No. of cases (%) |
|---|---|
|
| |
| Median age, years (range) | 51 (24–74) |
| Gender, male (%) | 47 (88.46%) |
| Etiology (%) | |
| HBV positive | 44 (84.61%) |
| HCV positive | 8 (15.39%) |
| ECOG PS (%) | |
| 0 | 16 (30.76%) |
| 1 | 28 (53.84%) |
| 2 | 6 (15.40%) |
| AFP (%) | |
| Normal | 12 (23.10%) |
| Elevated | 40 (76.90%) |
| Extrahepatic metastasis (%) | 34 (65.38%) |
| LN metastasis (%) | 23 (44.23%) |
| Portal vein invasion (%) | 36 (69.23%) |
| Child–Pugh (%) | |
| A | 8 (15.38%) |
| B | 32 (61.53%) |
| C | 12 (23.09%) |
| Median size of index tumor, cm (range) | 4.2 (1–13.3) |
| Median number of index tumors | 3 (1–5) |
| Prior local therapy (%) | None |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LN, lymph node.